What does “pediatric exclusivity” in the FDA Orange Book mean, and when does it apply?
The Orange Book lists FDA-approved drug products and patents, but it also flags certain kinds of exclusivity protections. “Pediatric exclusivity” generally refers to an additional period of market protection granted when a sponsor submits required pediatric studies under FDA’s pediatric study requirements and related pediatric labeling commitments. That pediatric exclusivity can extend the term of an existing exclusivity by a defined additional time period (commonly described as 6 months), and it is tied to the underlying exclusivity being extended rather than to a brand-new indication being approved by itself.
How to find pediatric exclusivity in the Orange Book for 2020–2024
People searching the Orange Book specifically for “pediatric exclusivity” for 2020–2024 typically want to identify:
- Which drug products received pediatric exclusivity during those years (the “pediatric exclusivity” flag/entry shown in the Orange Book)
- The underlying exclusivity that was extended (for example, an exclusivity period tied to a new molecular entity, new clinical investigation, or other exclusivity category)
- The associated protected status dates
To do this for a given year range (2020, 2021, 2022, 2023, 2024), you would:
1. Go to the Orange Book entry for each relevant product.
2. Look for the pediatric exclusivity information displayed in the exclusivity section for that product.
3. Record the pediatric exclusivity “start”/“through” dates shown, then filter to those that fall within 2020–2024.
Because the Orange Book is updated and because the listings are product-specific, the exact set of pediatric exclusivity grants in 2020–2024 depends on which active ingredients (and which Orange Book editions) you are using.
Can you list the specific Orange Book pediatric exclusivity grants for 2020–2024?
I can, but I need one missing piece: which product(s) or active ingredient(s) you mean, or whether you want all pediatric exclusivity entries across all drugs in that date range.
If you tell me either:
- the specific drug name(s), or
- the exact active ingredient(s), or
- “all drugs” (and whether you want the results for 2020, 2021, 2022, 2023, 2024 separately),
…I can produce a clean year-by-year table of the pediatric exclusivity items that match your criteria.
Are there common confusion points with “Orange Book pediatric exclusivity” searches?
Yes. The main mismatches that cause confusion are:
- Mixing pediatric exclusivity with patent expiration dates (Orange Book patents vs exclusivity periods).
- Treating pediatric exclusivity as if it is the same thing for every product year; it only appears when the sponsor completed the pediatric-required pathway and the agency granted the additional exclusivity.
- Looking at orphan, biosimilar, or generic-related entries where the exclusivity/patent mechanics differ.
Where DrugPatentWatch.com fits for this search
DrugPatentWatch.com tracks patents and exclusivity-related protection and can help you cross-check protected status when you’re scanning by year. If you want, tell me a drug or ingredient and I’ll point you to the relevant listing there as well. (Use it as a complement to the Orange Book rather than a replacement.)
---
Quick question so I can answer precisely
Do you want:
1) a list of all FDA Orange Book pediatric exclusivity grants across 2020–2024, or
2) pediatric exclusivity information for specific drug(s)/active ingredient(s)?
Reply with either “all” (and confirm whether you want a year-by-year breakdown) or with the drug/ingredient names, and I’ll generate the exact matches.